DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia

Information source: University of Alabama at Birmingham
Information obtained from ClinicalTrials.gov on November 03, 2008
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: ADHD With Sleep Onset Insomnia

Intervention: ramelteon or placebo (Drug); ramelteon (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: University of Alabama at Birmingham

Overall contact:
Roberta S. May, MA, Phone: 205-934-2484, Email: rmay@uabmc.edu

Summary

Primary: We hypothesize a clinically significant improvement in sleep latency, sleep-onset and total sleep time measures in adults with ADHD when given a trial of Ramelteon compared to placebo. Secondary: We expect that Ramelteon will show statistically significant improvements vs. placebo in measures of daytime sleepiness and with no decrement in daytime functioning, including such specific items as focus and social and occupational functioning.

Clinical Details

Official title: Ramelteon for Treatment of Adult Patients With ADHD-Related Insomnia

Study design: Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Crossover Assignment, Efficacy Study

Primary outcome: ADHD Rating Scale

Secondary outcome: CGI

Detailed description: Method: 8-week, randomized, double-blind, placebo-controlled crossover trial of Ramelteon in adult ADHD subjects who suffer from initial insomnia.

Eligibility

Minimum age: 19 Years. Maximum age: 65 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Diagnosis of ADHD and insomnia-

- 19-65 years of age

- In good general health

- Negative pregnancy test

Exclusion Criteria:

- Current primary psychiatric diagnosis other than ADHD

- Positive urine drug screen for any sedative hypnotic or drugs of abuse

- Unstable medical condition

- HIV positive

- Seizure disorder

- Known hypersensitivity to Ramelteon

Locations and Contacts

Roberta S. May, MA, Phone: 205-934-2484, Email: rmay@uabmc.edu

University of Alabama at Birmingham, Birmingham, Alabama 35205, United States
Additional Information

Starting date: February 2008
Ending date: February 2010
Last updated: February 22, 2008

Page last updated: November 03, 2008

-- advertisement -- The American Red Cross
We comply with
HONcode standard.
Verify here.
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2009